Highlights from

WCD 2019

World Congress of Dermatology

Milan 10-15 June 2019

New targets and biologics for cutaneous lupus erythematosus

Prof. Victoria P. Werth (University of Pennsylvania, USA) pointed out the need for new therapeutics in cutaneous lupus erythematosus (CLE) for patients resistant to conventional immunosuppressive agents [1].

Most therapeutic trials with novel agents focus on systemic lupus erythematosus (SLE) and exclude CLE patients. However, CLE and SLE share the same pathology. To solve this gap, a lupus community panel proposed to optimise future clinical trials [2]. If skin improvement is strong enough when nested in a SLE study, treatment should be made available for patients with CLE irrespective of whether they meet SLE classification. A couple of biologics have shown activity in CLE, including the IL-12/IL-23 inhibitor ustekinumab. Ustekinumab was shown to result in significant improvement in disease activity, assessed in the responder index 4 in the SLE disease activity index 2000 (SLEDAI-2K) [3].

B cells: an important novel target

The hallmark of lupus is dysregulation of B cells. B-cell-targeted therapies are therefore the focus of recent clinical research. Biologics targeting B cells are belimumab and rituximab. Belimumab is an antibody binding to the B lymphocyte stimulator (BLys), a factor involved in the survival or differentiation of B cells. The agent has shown to improve overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains [4]. The chimeric anti-CD20 monoclonal antibody rituximab has been used with success in recalcitrant lupus manifestations [5].

Another approach: JAK inhibitors and IFNAR antibodies

First data from a double-blind, placebo-controlled, phase 2 trial with the Janus Kinase (JAK)1 and JAK2 inhibitor baricitinib showed that the 4 mg dose significantly improved signs and symptoms of active SLE in patients who were not adequately controlled despite standard-of-care therapy [6]. However, patients included in this trial had low skin activity, and showed no improvement in skin symptoms.

The type I interferon (IFN) system plays a key role in SLE pathogenesis: increased expression of type I IFN-regulated proteins can be found in the blood and target tissues of patients with CLE and SLE [7]. Cell signalling by all type I IFNs is mediated by the IFN-alpha receptor (IFNAR) [8]. This is the rationale for developing IFNAR antibodies. In a phase 2b, randomised, double-blind, placebo-controlled study, the efficacy and safety of the IFNAR antagonist anifrolumab was assessed [9]. Therapy with anifrolumab led to an at least 50% improvement in the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in patients with CLASI activity score ≥10 at baseline [9]. In this study, therapy had a greater effect size in patients with a high IFN signature at baseline.

Prof. Werth concluded that “SLE patients will probably benefit most from combination therapy – similar to the situation in oncology.”

Top image: @ iStockPhoto: AzmanL

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.